Fielder Capital Group LLC Purchases New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Key Points

• Fielder Capital Group LLC acquired a new stake in Vertex Pharmaceuticals, purchasing 533 shares valued at approximately $258,000 during the first quarter.
• Analysts have revised their ratings on Vertex Pharmaceuticals, with many shifting from "strong-buy" to "hold," while a consensus rating remains a "Moderate Buy" with an average target price of $512.30.
• Vertex Pharmaceuticals reported a quarterly earnings miss, posting earnings of $4.06 per share, which fell short of the consensus estimate of $4.29, while revenue was up 2.6% year-over-year at $2.77 billion.

Fielder Capital Group LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 533 shares of the pharmaceutical company's stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Foundations Investment Advisors LLC lifted its stake in Vertex Pharmaceuticals by 17.7% in the 1st quarter. Foundations Investment Advisors LLC now owns 993 shares of the pharmaceutical company's stock valued at $481,000 after buying an additional 149 shares in the last quarter. Maridea Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the 1st quarter valued at about $452,000. Baldwin Investment Management LLC lifted its stake in Vertex Pharmaceuticals by 10.1% in the 1st quarter. Baldwin Investment Management LLC now owns 13,830 shares of the pharmaceutical company's stock worth $6,705,000 after purchasing an additional 1,271 shares in the last quarter. Prosperity Consulting Group LLC lifted its stake in Vertex Pharmaceuticals by 2.9% in the 1st quarter. Prosperity Consulting Group LLC now owns 3,004 shares of the pharmaceutical company's stock worth $1,456,000 after purchasing an additional 85 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in Vertex Pharmaceuticals by 27.8% in the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 1,454 shares of the pharmaceutical company's stock worth $705,000 after purchasing an additional 316 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VRTX has been the topic of a number of research reports. Leerink Partnrs lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Royal Bank Of Canada set a $420.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "sector perform" rating in a research note on Tuesday, June 17th. Finally, Leerink Partners reissued a "market perform" rating and issued a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $512.30.

Vertex Pharmaceuticals Stock Down 0.6%

Vertex Pharmaceuticals stock opened at $469.65 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The firm has a 50 day moving average price of $453.13 and a 200 day moving average price of $465.42. The company has a market capitalization of $120.61 billion, a PE ratio of -119.81 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business's revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $4.76 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.